Search Results

There are 3896540 results for: content related to: Induction of mania in depression by paroxetine

  1. You have free access to this content
    Paroxetine versus other anti-depressive agents for depression

    Intervention Review

    The Cochrane Library

    Marianna Purgato, Davide Papola, Chiara Gastaldon, Carlotta Trespidi, Laura R Magni, Carla Rizzo, Toshi A Furukawa, Norio Watanabe, Andrea Cipriani and Corrado Barbui

    Published Online : 3 APR 2014, DOI: 10.1002/14651858.CD006531.pub2

  2. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine

    Acta Psychiatrica Scandinavica

    Volume 122, Issue 3, September 2010, Pages: 246–254, M. L. M. Van Der Loos, P. Mulder, E. G. Th. M. Hartong, M. B. J. Blom, A. C. Vergouwen, M. S. Van Noorden, M. A. Timmermans, E. Vieta, W. A. Nolen and for the LamLit Study Group

    Version of Record online : 5 FEB 2010, DOI: 10.1111/j.1600-0447.2009.01537.x

  3. You have free access to this content
    Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013

    Bipolar Disorders

    Volume 15, Issue 1, February 2013, Pages: 1–44, Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, Serge Beaulieu, Martin Alda, Claire O’Donovan, Glenda MacQueen, Roger S McIntyre, Verinder Sharma, Arun Ravindran, L Trevor Young, Roumen Milev, David J Bond, Benicio N Frey, Benjamin I Goldstein, Beny Lafer, Boris Birmaher, Kyooseob Ha, Willem A Nolen and Michael Berk

    Version of Record online : 12 DEC 2012, DOI: 10.1111/bdi.12025

  4. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age

    Human Psychopharmacology: Clinical and Experimental

    Volume 19, Issue 6, August 2004, Pages: 405–408, Shigeru Morishita and Seizaburo Arita

    Version of Record online : 21 JUN 2004, DOI: 10.1002/hup.608

  5. Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies

    Rapid Communications in Mass Spectrometry

    Volume 17, Issue 13, 15 July 2003, Pages: 1455–1461, Mireia Segura, Jordi Ortuño, Magí Farré, Roberta Pacifici, Simona Pichini, Jesús Joglar, Jordi Segura and Rafael de la Torre

    Version of Record online : 22 MAY 2003, DOI: 10.1002/rcm.1067

  6. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response

    Acta Psychiatrica Scandinavica

    Volume 95, Issue 4, April 1997, Pages: 288–296, O. Benkert, A. Szegedi, H. Wetzel, H. J. Staab, W. Meister and M. Philipp

    Version of Record online : 13 NOV 2007, DOI: 10.1111/j.1600-0447.1997.tb09634.x

  7. You have free access to this content

    Progress in Neurology and Psychiatry

    Volume 12, Issue 9, November/December 2008, Pages: 36–39,

    Version of Record online : 3 DEC 2008, DOI: 10.1002/pnp.104

  8. The Clinical Pharmacology and Use of Paroxetine, a New Selective Serotonin Reuptake Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 14, Issue 2, March-April 1994, Pages: 127–138, Charles B. Nemeroff

    Version of Record online : 18 JAN 2012, DOI: 10.1002/j.1875-9114.1994.tb02799.x

  9. You have free access to this content
    Paroxetine: A Review

    CNS Drug Reviews

    Volume 7, Issue 1, March 2001, Pages: 25–47, Michel Bourin, Pierre Chue and Yannick Guillon

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2001.tb00189.x

  10. Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: A meta-analysis

    Asia-Pacific Psychiatry

    Volume 6, Issue 4, December 2014, Pages: 353–362, Ying Wang, Lehua Yu, Jing Xie, Jianjun Chen and Qianping Wei

    Version of Record online : 22 OCT 2013, DOI: 10.1111/appy.12106

  11. PEM report number 6. Paroxetine

    Pharmacoepidemiology and Drug Safety

    Volume 2, Issue 4-5, July - October 1993, Pages: 393–422, William Inman, Kiyoshi Kubota, Gillian Pearce and Lynda Wilton

    Version of Record online : 31 JAN 2006, DOI: 10.1002/pds.2630020409

  12. Persistent benefits of slow titration of paroxetine in a six-month follow-up

    Human Psychopharmacology: Clinical and Experimental

    Volume 30, Issue 5, September 2015, Pages: 329–333, Paolo Olgiati and Alessandro Serretti

    Version of Record online : 21 APR 2015, DOI: 10.1002/hup.2478

  13. Poster Session: Clinical Diagnosis and Comorbidity

    Bipolar Disorders

    Volume 10, Issue s1, January 2008, Pages: 30–90,

    Version of Record online : 24 JAN 2008, DOI: 10.1111/j.1399-5618.2007.00569.x

    Corrected by:


    Vol. 10, Issue 3, 451, Version of Record online: 8 APR 2008

  14. Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

    The Journal of Clinical Pharmacology

    Volume 42, Issue 11, November 2002, Pages: 1219–1227, Dr. Donna J. Belle, C. Steven Ernest, John-Michael Sauer, Brian P. Smith, Holly R. Thomasson and Jennifer W. Witcher

    Version of Record online : 8 MAR 2013, DOI: 10.1177/009127002762491307

  15. You have free access to this content

    Progress in Neurology and Psychiatry

    Volume 13, Issue 1, January/February 2009, Pages: 34–35,

    Version of Record online : 23 FEB 2009, DOI: 10.1002/pnp.111

  16. Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 36, Issue 1, February 2013, Pages: 51–58, Y. R. A. Van ZEELAND, N. J. SCHOEMAKER, A. HARITOVA, J. W. SMIT, E. M. Van MAARSEVEEN, J. T. LUMEIJ and J. FINK-GREMMELS

    Version of Record online : 21 MAR 2012, DOI: 10.1111/j.1365-2885.2012.01391.x

  17. Effects of Paroxetine on the Pharmacokinetics and Pharmacodynamics of Immediate-Release and Extended-Release Metoprolol

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 7, July 2011, Pages: 630–641, Dr. Robert B. Parker and Dr. Judith E. Soberman

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.7.630

  18. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

    Clinical Pharmacology & Therapeutics

    Volume 70, Issue 4, October 2001, Pages: 327–335, Kari Laine, Gunnel Tybring, Sebastian Härtter, Katarina Andersson RN, Jan-Olof Svensson, Jolanta Widén and Leif Bertilsson

    Version of Record online : 12 OCT 2001, DOI: 10.1016/S0009-9236(01)78384-1

  19. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients

    Acta Psychiatrica Scandinavica

    Volume 89, Issue 6, June 1994, Pages: 382–389, S.-L. Arminen, U. Ikonen, P. Pulkkinen, E. Leinonen, A. Mahlanen, H. Koponen, K. Kourula, J. Ryyppö, V. Korpela, M. L. Lehtonen, H. Vartiainen, V. Lehtinen, T. Tamminen and P. M. Manniche

    Version of Record online : 23 AUG 2007, DOI: 10.1111/j.1600-0447.1994.tb01533.x

  20. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 6, November 2014, Pages: 568–577, William A. Ball, Duane B. Snavely, Richard J. Hargreaves, Armin Szegedi, Christopher Lines and Scott A. Reines

    Version of Record online : 20 OCT 2014, DOI: 10.1002/hup.2444